Related Experiment Video
Updated: Nov 3, 2025
High Throughput, Real-time, Dual-readout Testing of Intracellular Antimicrobial Activity and Eukaryotic Cell Cytotoxicity
Published on: November 16, 2016
Use of glucocorticoids and azithromycin in the therapy of COVID-19
Miguel de Lemos Neto1, Rafael Costa Vieira Alexandre2, Rafaela Oliveira Gallart Morra2
1Faculty of Medicine of Campos dos Goytacazes, Av. Alberto Torres, 217, Campos dos Goytacazes, Brazil.
Abstract:
In December 2019, a new variant coronavirus, SARS-CoV-2, emerged in China, which was initially described as a pneumonia of an unknown agent. The new coronavirus spreads mainly by person-to-person transmission through close contact. The pathophysiology of COVID-19 is related to a complex immune system response that varies between people and, in severe cases of the disease, is characterized by excessive responses called "cytokine storms," which are associated with complications that can lead to a state of hypercoagulation and death. Glucocorticoids and azithromycin are drugs that may be effective in the treatment. This review aims to highlight the clinical findings that demonstrate the effectiveness of glucocorticoid and azithromycin therapy in the treatment of COVID-19. To date, many drugs have been studied for use in combination therapy, and the rapid expansion of knowledge about the virology of SARS-CoV-2 generates a more accurate direction in therapy.
Insights
This review highlights the effectiveness of glucocorticoids and azithromycin in treating COVID-19. These therapies show promise in managing the severe immune responses associated with SARS-CoV-2 infection.
Area of Science:
- Infectious Diseases
- Immunology
- Pharmacology
Background:
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) emerged in late 2019, causing COVID-19.
- COVID-19 pathophysiology involves complex immune responses, including dangerous cytokine storms in severe cases.
- Cytokine storms can lead to hypercoagulation, multi-organ failure, and death.
Purpose of the Study:
- To review clinical findings on the efficacy of glucocorticoid and azithromycin therapy for COVID-19.
- To summarize current knowledge on SARS-CoV-2 treatment strategies.
- To explore the role of combination therapy in managing COVID-19.
Main Methods:
- Literature review of clinical studies and case reports.
- Analysis of data on the therapeutic effects of glucocorticoids and azithromycin.
- Synthesis of information on SARS-CoV-2 virology and disease progression.
Main Results:
- Glucocorticoids and azithromycin demonstrate potential effectiveness in treating COVID-19.
- These medications may help mitigate severe immune responses and associated complications.
- Combination therapy approaches are under active investigation.
Conclusions:
- Glucocorticoid and azithromycin therapy show promise for managing COVID-19.
- Further research is needed to optimize treatment protocols.
- Advancing knowledge of SARS-CoV-2 virology guides therapeutic development.
More Related Videos
Related Concept Videos
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:14Myocarditis III: Medical Management
01:29Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...